Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04999202
Title A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | GBR

Facility Status City State Zip Country Details
Florida Cancer Specialists Altamonte Springs Florida 32701 United States Details
Florida Cancer Specialists & Research Institute Sarasota Florida 34232 United States Details
Henry Ford Hospital Detroit Michigan 48202 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Texas Oncology- Austin Midtown Austin Texas 78705 United States Details
Virginia Cancer Specialists, PC Fairfax Virginia 22031 United States Details
Istituto Nazionale Tumori IRCCS Fondazione G.Pascale Napoli Campania 80131 Italy Details
Istituto Clinico Humanitas - Humanitas Mirasole S.p.A. Milano Lombardia 20089 Italy Details
Fondazione IRCCS Istituto Nazionale dei Tumori Milano Lombardia 20133 Italy Details
IRCCS Istituto Europeo di Oncologia s.r.l. (IEO) Milano Lombardia 20141 Italy Details
National University Hospital Singapore 119228 Singapore Details
Belfast City Hospital Belfast North Ireland BT12 7AB United Kingdom Details
Freeman Hospital Newcastle Tyne And Wear NE7 7DN United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field